LFM-A13, the first small-molecule inhibitor of Bruton’s tyrosine kinase (BTK), has demonstrated efficacy in curbing tumor growth (Mahajan et al., 1999), with additional anti-proliferative and pro-apoptotic effects observed in breast cancer models (Rozkiewicz et al., 2020). Here, BTK is linked to breast cancer.